Enhanced cellular immunity in macaques following a novel peptide immunotherapy.
Advances in treating and preventing AIDS depend on understanding how human immunodeficiency virus (HIV) is eliminated in vivo and on the manipulation of effective immune responses to HIV. During the development of assays quantifying the elimination of fluorescent autologous cells coated with overlapping 15-mer simian immunodeficiency virus (SIV) or HIV-1 peptides, we made a remarkable observation: the reinfusion of macaque peripheral blood mononuclear cells, or even whole blood, pulsed with SIV and/or HIV peptides generated sharply enhanced SIV- and HIV-1-specific T-cell immunity. Strong, broad CD4+- and CD8+-T-cell responses could be enhanced simultaneously against peptide pools spanning 87% of all SIV- and HIV-1-expressed proteins-highly desirable characteristics of HIV-specific immunity. De novo hepatitis C virus-specific CD4+- and CD8+-T-cell responses were generated in macaques by the same method. This simple technique holds promise for the immunotherapy of HIV and other chronic viral infections.
Chea
S
S
Department of Microbiology and Immunology, University of Melbourne, Victoria 3010, Australia.
Dale
C J
CJ
De Rose
R
R
Ramshaw
I A
IA
Kent
S J
SJ
D000818:Animals; D016913:Blood Component Transfusion; D001803:Blood Transfusion; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D004195:Disease Models, Animal; D006678:HIV / Q000276:immunology*; D015488:HIV Antigens / Q000008:administration & dosage / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D006526:Hepatitis C / Q000276:immunology; D018936:Hepatitis C Antigens / Q000008:administration & dosage / Q000276:immunology; D007167:Immunotherapy; D008254:Macaca nemestrina; D010455:Peptides / Q000008:administration & dosage / Q000276:immunology*; D012191:Retroviridae Proteins / Q000008:administration & dosage / Q000276:immunology; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000628:therapy*; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
D015488:HIV Antigens; D018936:Hepatitis C Antigens; D010455:Peptides; D012191:Retroviridae Proteins
Immunol Lett. 2001 Nov 1;79(1-2):57-61
11595290
J Immunol Methods. 2001 Sep 1;255(1-2):27-40
11470284
Nature. 2002 Jan 17;415(6869):331-5
11797011
Nature. 2002 May 2;417(6884):95-8
11986671
J Immunol. 2002 Jun 1;168(11):5954-8
12023402
Virology. 2002 Sep 15;301(1):176-87
12359458
J Immunother. 2002 Nov-Dec;25(6):500-8
12439347
Nat Med. 2003 Jan;9(1):27-32
12496959
Cancer Immunol Immunother. 2003 Jan;52(1):41-52
12536239
J Infect Dis. 2003 Jan 15;187(2):226-42
12552447
Eur J Immunol. 2003 Jun;33(6):1557-67
12778473
J Immunol Methods. 2003 Dec;283(1-2):141-53
14659906
J Virol. 1994 Jul;68(7):4650-5
8207839
J Virol. 1994 Sep;68(9):6103-10
8057491
J Immunol. 1997 Jan 15;158(2):807-15
8992998
Immunity. 1997 May;6(5):519-29
9175830
Science. 1997 Nov 21;278(5342):1447-50
9367954
J Virol. 1998 Dec;72(12):10180-8
9811759
J Immunol. 1998 Nov 15;161(10):5338-46
9820507
Science. 1999 Feb 5;283(5403):857-60
9933172
Clin Infect Dis. 1999 Mar;28(3):541-7
10194075
Science. 1999 Apr 30;284(5415):816-9
10221916
Nat Med. 1999 May;5(5):526-34
10229229
J Virol. 1999 Sep;73(9):7524-32
10438842
Vaccine. 2004 Nov 25;23(2):188-97
15531036
J Virol. 2004 Dec;78(24):13819-28
15564490
Immunol Rev. 1999 Aug;170:127-34
10566147
J Virol. 2000 Mar;74(6):2502-9
10684264
J Exp Med. 2000 May 1;191(9):1499-512
10790425
Nature. 2000 Sep 28;407(6803):523-6
11029005
Science. 2000 Oct 20;290(5491):486-92
11039923
J Virol. 2001 Feb;75(4):1990-5
11160699
Science. 2001 Apr 6;292(5514):69-74
11393868
Int Immunol. 2002 Jan;14(1):31-7
11751749